EPS for Novavax, Inc. (NVAX) Expected At $-0.12

October 13, 2018 - By Winifred Garcia

Novavax, Inc. (NASDAQ:NVAX) LogoInvestors sentiment increased to 2.11 in Q2 2018. Its up 0.55, from 1.56 in 2018Q1. It is positive, as 16 investors sold Novavax, Inc. shares while 21 reduced holdings. 25 funds opened positions while 53 raised stakes. 160.47 million shares or 7.74% more from 148.94 million shares in 2018Q1 were reported.
Group One Trading L P invested 0% in Novavax, Inc. (NASDAQ:NVAX). First Allied Advisory Svcs Inc accumulated 0.01% or 100,500 shares. Susquehanna Intl Group Inc Ltd Liability Partnership holds 841,728 shares. Quantitative Inv Ltd Com invested 0.01% in Novavax, Inc. (NASDAQ:NVAX). Commercial Bank Of Montreal Can holds 0% or 2,709 shares in its portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) accumulated 7,214 shares or 0% of the stock. Prudential Fincl Inc holds 0% of its portfolio in Novavax, Inc. (NASDAQ:NVAX) for 37,253 shares. Valley Advisers Inc reported 500 shares stake. Balyasny Asset Ltd Company accumulated 493,820 shares. Fisher Asset Management Ltd Liability reported 143,965 shares. Bancshares Of America Corp De invested in 521,460 shares or 0% of the stock. Moreover, Ameritas Invest Prns Inc has 0% invested in Novavax, Inc. (NASDAQ:NVAX) for 32,730 shares. Legal And General Gru Public invested in 56,814 shares. Renaissance Ltd Llc, a New York-based fund reported 5.79 million shares. California State Teachers Retirement System owns 583,412 shares.

Since May 14, 2018, it had 3 insider purchases, and 0 insider sales for $208,866 activity. 20,000 shares valued at $32,800 were bought by Glenn Gregory M on Monday, May 14.

Analysts expect Novavax, Inc. (NASDAQ:NVAX) to report $-0.12 EPS on November, 6.They anticipate $0.03 EPS change or 20.00 % from last quarter’s $-0.15 EPS. After having $-0.12 EPS previously, Novavax, Inc.’s analysts see 0.00 % EPS growth. The stock increased 3.14% or $0.06 during the last trading session, reaching $1.97. About 4.12M shares traded. Novavax, Inc. (NASDAQ:NVAX) has risen 28.07% since October 14, 2017 and is uptrending. It has outperformed by 12.45% the S&P500.

Novavax, Inc. (NASDAQ:NVAX) Ratings Coverage

Among 2 analysts covering Novavax (NASDAQ:NVAX), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Novavax had 2 analyst reports since May 17, 2018 according to SRatingsIntel. The company was maintained on Thursday, May 17 by FBR Capital. The company was upgraded on Friday, September 21 by JP Morgan.

Novavax, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of recombinant nanoparticle vaccines and adjuvants. The company has market cap of $753.71 million. The firm develops respiratory syncytial virus fusion protein nanoparticle vaccine candidate for infants via maternal immunization in Phase III development stage; older adults in Phase II development stage; and children six months to five years of age in Phase I development stage. It currently has negative earnings. It also develops Ebola GP vaccine in Phase 1 clinical trial; preclinical programs for Zika virus; and seasonal influenza and a combination respiratory vaccine candidate, as well as other infectious disease vaccine candidates.

More notable recent Novavax, Inc. (NASDAQ:NVAX) news were published by: Fool.com which released: “Here’s Why Novavax Gained 20.5% in September” on October 10, 2018, also Seekingalpha.com with their article: “Novavax, Inc. (NVAX) Presents at Ladenburg Thalmann 2018 Healthcare Conference (Transcript)” published on October 02, 2018, Seekingalpha.com published: “Novavax Shares Strengthen As A Key Catalyst Approaches” on September 25, 2018. More interesting news about Novavax, Inc. (NASDAQ:NVAX) were released by: Fool.com and their article: “Why Novavax Inc. Is Surging 14.4% Higher Today” published on September 24, 2018 as well as Benzinga.com‘s news article titled: “ResVax, NanoFlu Prospects Earn Novavax A Double Upgrade” with publication date: September 21, 2018.

Novavax, Inc. (NASDAQ:NVAX) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.